Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
- PMID: 26860295
- PMCID: PMC4747949
- DOI: 10.1186/s13550-016-0171-1
Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
Abstract
Background: The radiolanthanide (161)Tb has, in recent years, attracted increasing interest due to its favorable characteristics for medical application. (161)Tb exhibits similar properties to the widely-used therapeutic radionuclide (177)Lu. In contrast to (177)Lu, (161)Tb yields a significant number of short-ranging Auger/conversion electrons (≤50 keV) during its decay process. (161)Tb has been shown to be more effective for tumor therapy than (177)Lu if applied using the same activity. The purpose of this study was to investigate long-term damage to the kidneys after application of (161)Tb-folate and compare it to the renal effects caused by (177)Lu-folate.
Methods: Renal side effects were investigated in nude mice after the application of different activities of (161)Tb-folate (10, 20, and 30 MBq per mouse) over a period of 8 months. Renal function was monitored by the determination of (99m)Tc-DMSA uptake in the kidneys and by measuring blood urea nitrogen and creatinine levels in the plasma. Histopathological analysis was performed by scoring of the tissue damage observed in HE-stained kidney sections from euthanized mice.
Results: Due to the co-emitted Auger/conversion electrons, the mean absorbed renal dose of (161)Tb-folate (3.0 Gy/MBq) was about 24 % higher than that of (177)Lu-folate (2.3 Gy/MBq). After application of (161)Tb-folate, kidney function was reduced in a dose- and time-dependent manner, as indicated by the decreased renal uptake of (99m)Tc-DMSA and the increased levels of blood urea nitrogen and creatinine. Similar results were obtained when (177)Lu-folate was applied at the same activity. Histopathological investigations confirmed comparable renal cortical damage after application of the same activities of (161)Tb-folate and (177)Lu-folate. This was characterized by collapsed tubules and enlarged glomeruli with fibrin deposition in moderately injured kidneys and glomerulosclerosis in severely damaged kidneys.
Conclusions: Tb-folate induced dose-dependent radionephropathy over time, but did not result in more severe damage than (177)Lu-folate when applied at the same activity. These data are an indication that Auger/conversion electrons do not exacerbate overall renal damage after application with (161)Tb-folate as compared to (177)Lu-folate, even though they result in an increased dose deposition in the renal tissue. Global toxicity affecting other tissues than kidneys remains to be investigated after (161)Tb-based therapy, however.
Keywords: 161Tb; 177Lu; Auger/conversion electrons; Kidney; Radiofolate; Radionephropathy; Radionuclide therapy.
Figures




Similar articles
-
Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy.Nucl Med Biol. 2015 Oct;42(10):770-9. doi: 10.1016/j.nucmedbio.2015.06.006. Epub 2015 Jun 11. Nucl Med Biol. 2015. PMID: 26162583
-
Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):476-85. doi: 10.1007/s00259-013-2563-z. Epub 2013 Oct 8. Eur J Nucl Med Mol Imaging. 2014. PMID: 24100768
-
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1919-1930. doi: 10.1007/s00259-019-04345-0. Epub 2019 May 27. Eur J Nucl Med Mol Imaging. 2019. PMID: 31134301 Free PMC article.
-
Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.Br J Radiol. 2018 Nov;91(1091):20180074. doi: 10.1259/bjr.20180074. Epub 2018 Jun 15. Br J Radiol. 2018. PMID: 29658792 Free PMC article. Review.
-
Preclinical development of small-molecular-weight folate-based radioconjugates: a pharmacological perspective.Q J Nucl Med Mol Imaging. 2015 Sep;59(3):269-86. Epub 2015 Jul 7. Q J Nucl Med Mol Imaging. 2015. PMID: 26149341 Review.
Cited by
-
PMMA-Based Continuous Hemofiltration Modulated Complement Activation and Renal Dysfunction in LPS-Induced Acute Kidney Injury.Front Immunol. 2021 Apr 1;12:605212. doi: 10.3389/fimmu.2021.605212. eCollection 2021. Front Immunol. 2021. PMID: 33868226 Free PMC article.
-
Preclinical in vivo application of (152)Tb-DOTANOC: a radiolanthanide for PET imaging.EJNMMI Res. 2016 Dec;6(1):35. doi: 10.1186/s13550-016-0189-4. Epub 2016 Apr 23. EJNMMI Res. 2016. PMID: 27108447 Free PMC article.
-
Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides.EJNMMI Res. 2020 Mar 2;10(1):16. doi: 10.1186/s13550-020-0612-8. EJNMMI Res. 2020. PMID: 32124111 Free PMC article.
-
Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".Pharmaceutics. 2021 Jun 18;13(6):906. doi: 10.3390/pharmaceutics13060906. Pharmaceutics. 2021. PMID: 34207408 Free PMC article. Review.
-
First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC.J Nucl Med. 2021 Oct;62(10):1391-1397. doi: 10.2967/jnumed.120.258376. Epub 2021 Feb 5. J Nucl Med. 2021. PMID: 33547209 Free PMC article.
References
-
- Nuclear National Data Center (Upton N.Y.) NuDat 2.6. http://www.nndc.bnl.gov/nudat2/.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous